
|Videos|October 6, 2021
Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB
Author(s)Urology Times staff
“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.
Advertisement
In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










